Meta-Analysis
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jun 14, 2015; 21(22): 7022-7035
Published online Jun 14, 2015. doi: 10.3748/wjg.v21.i22.7022
Table 1 Included studies on efficacy of cetuximab plus chemotherapy vs chemotherapy alone in patients with metastatic or advanced colorectal cancer
StudyType of articlePatientsIntervention
Main endpointsMutation status reported
Quality control
Cetuximab + chemotherapyChemotherapy(HR, 95%CI)KRASBRAF
Borner et al[27]Full manuscript74Cetuximab + XELOXXELOXPFS: NR; OS: NRNoNoModerate
Bokemeyer et al[25]Full manuscript337Cetuximab + FOLFOX-4FOLFOX-4PFS: 0.931, 0.705-1.230;YesYesGood
OS: 1.015, 0.791-1.303
Van Cutsem et al[21]Full manuscript1198Cetuximab + FOLFIRIFOLFIRIPFS: 0.851, 0.726-0.998;YesYesGood
OS: 0.878, 0.774-0.995
Maughan et al[17]Full manuscript1630Cetuximab + oxaliplatin + fluoropyrimidineOxaliplatin + fluoropyrimidinePFS: 0.96, 0.82-1.12;YesYesGood
OS: 1.04, 0.87-1.23
Tveit et al[22]Full manuscript571Cetuximab + FLOXFLOXPFS: NR; OS: NRYesYesGood
Alberts et al[26]Full manuscript2686Cetuximab + mFOLFOX6mFOLFOX6PFS: NR; OS: NRYesYesGood
Huang et al[24]Full manuscript146Cetuximab + FOLFIRIFOLFIRIPFS: 0.53, 0.26-1.10;YesYesGood
OS: 0.45, 0.2-1.2
Ye et al[23]Full manuscript138Cetuximab + mFOLFOX6/ FOLFIRImFOLFOX6/PFS: 0.60, 0.41-0.87;YesYesGood
FOLFIRIOS: 0.54, 0.33-0.89
Table 2 Adverse events (grade 3 and 4)
StudyNeutropenia
Nausea and vomiting
Skin toxicity/rash
Rash
Diarrhea
Control groupCetuximab groupControl groupCetuximab groupControl groupCetuximab groupControl groupCetuximab groupControl groupCetuximab group
Borner et al[27]30610016081622
Bokemeyer et al[25]5751NANA1301191214
Van Cutsem et al[21]150169302811170496394
Maughan et al[17]NANANANA14114NANANANA
Tveit et al[22]47953141511511033
Alberts et al[26]891105970NANA318683148
Huang et al[24]153018NANA011156
Ye et al[23]6833122934